Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tecan Group (TCGGY) Fair Value & Analysis

Healthcare · US · Market cap $2.3B

Price$36.00
Fair Value$22.54
Upside-37.4%
Quality95/100
Evidence: High Range $16.74 – $28.35

Fair value as of: Jun 24, 2026

Analysis

Tecan Group (TCGGY) currently trades at $36.00, while our model-based Fair Value estimate is $22.54 — implying the stock looks roughly 37.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Tecan Group (TCGGY) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $22.54 versus a price of $36.00 — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of TCGGY?
Our 21-model fair value for Tecan Group is $22.54 (as of Jun 24, 2026), built from audited fundamentals. The current price is $36.00.
What is the quality score of TCGGY?
Tecan Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.